Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

NAPRELAN CR 375 MG TABLET

Naproxen Sodium
$17.8402per EA
High Outlier

Strength

375 mg/1

Manufacturer

Almatica Pharma LLC

NDC

52427027201

Classification

Brand

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Route

ORAL

Last Updated

6/11/2014

Active Ingredients

NAPROXEN SODIUM

Approval Type

New Drug (NDA)

FDA Application

NDA020353

On Market Since

1/17/2014

Pharmacological Classes

Anti-Inflammatory Agents
Non-Steroidal
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

0.0%

5Y

0.0%

All

N/A

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

CHILDREN'S ADVIL 100 MG/5 ML
Brand
00573017030•Haleon US Holdings LLC
$0.0368
per ML
CHILDREN'S ADVIL 100 MG/5 ML
Brand
00573017130•Haleon US Holdings LLC
$0.0368
per ML
CHILDREN'S ADVIL 100 MG/5 ML
Brand
00573023230•Haleon US Holdings LLC
$0.0368
per ML
CHILDREN'S ADVIL 100 MG/5 ML
Brand
00573029030•Haleon US Holdings LLC
$0.0368
per ML
ADVIL 200 MG TABLET
Brand
00573015020•Haleon US Holdings LLC
$0.1081
per EA
ADVIL 200 MG TABLET
Brand
00573015030•Haleon US Holdings LLC
$0.1081
per EA
ADVIL 200 MG TABLET
Brand
00573015040•Haleon US Holdings LLC
$0.1081
per EA
ADVIL 200 MG TABLET
Brand
00573015110•Haleon US Holdings LLC
$0.1081
per EA
ADVIL 200 MG TABLET
Brand
00573015475•Haleon US Holdings LLC
$0.1081
per EA
ADVIL 200 MG TABLET
Brand
00573015498•Haleon US Holdings LLC
$0.1081
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy